Mast’s sickle cell drug flunks PhIII, eclipsing shares
Turn out the lights, the party is over at Mast Therapeutics. The San Diego-based biotech, a penny stock microcap, announced after the market closed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
